CNTA

Centessa Pharmaceuticals
CNTA

$10.78

5.54%

Market Cap: 1.22B

About: Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.

Employees: 75

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 3 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

367% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 6

181% more call options, than puts

Call options by funds: $216K | Put options by funds: $77K

157% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 7

150% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2023] → 5 (+3) [Q1 2024]

48% more capital invested

Capital invested by funds: $567M [Q4 2023] → $841M (+$273M) [Q1 2024]

19% more funds holding

Funds holding: 58 [Q4 2023] → 69 (+11) [Q1 2024]

3.19% more ownership

Funds ownership: 73.01% [Q4 2023] → 76.2% (+3.19%) [Q1 2024]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$11

2%

upside

Avg. target

$13.33

24%

upside

High target

$15

39%

upside

3 analyst ratings

2 positive

67%

1 neutral

33%

0 negative

0%

Oppenheimer Francois Brisebois	30%upside $14	Outperform Initiated	18 Jul 2024
Morgan Stanley Matthew Harrison	2%upside $11	Equal-Weight Maintained	21 Jun 2024
BMO Capital Kostas Biliouris	39%upside $15	Outperform Maintained	1 Apr 2024

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Wall Street Analysts Believe Centessa Pharmaceuticals (CNTA) Could Rally 48.85%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 48.9% in Centessa Pharmaceuticals (CNTA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Centessa Pharmaceuticals (CNTA) Could Rally 48.85%: Here's is How to Trade

Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer

BOSTON and LONDON, June 10, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that John Crowley CPA, has been appointed Chief Financial Officer, and Gregory Weinhoff MD MBA, former Chief Financial Officer, has been appointed to the newly created role of Chief Business Officer, effective June 10, 2024.

Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer

Zacks Investment Research

Down -10.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Centessa Pharmaceuticals (CNTA)

Centessa Pharmaceuticals (CNTA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down -10.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Centessa Pharmaceuticals (CNTA)

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

BOSTON and LONDON, May 21, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024

BOSTON and LONDON, May 13, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today reported financial results and business highlights for the first quarter ended March 31, 2024.

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024

Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point

Centessa Pharmaceuticals plc interim data from the PRESent-2 study, using SerpinPC for the treatment of patients with Hemophilia B without inhibitors, is expected to be released in 2024.

Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point

Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares

BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the pricing of an underwritten public offering of 10,810,810 American Depositary Shares (“ADSs”), each representing one ordinary share, at a price to the public of $9.25 per ADS. The aggregate gross proceeds to Centessa from this offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and offering expenses payable by Centessa. All ADSs sold in the offering were offered by Centessa. The offering is expected to close on or about April 26, 2024, subject to customary closing conditions. Centessa has also granted the underwriters a 30-day option to purchase up to an additional 1,621,621 ADSs at the public offering price, less underwriting discounts and commissions.

Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares

BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has commenced an underwritten public offering of $100 million of American Depositary Shares (“ADSs”), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a 30-day option to purchase up to an additional $15 million of ADSs offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024

BOSTON and LONDON, April 22, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug application (IND) to initiate a Phase 1 first-in-human, clinical trial of ORX750 for the treatment of narcolepsy. ORX750 is an investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1 (NT1), with potential applicability to narcolepsy type 2 (NT2), idiopathic hypersomnia (IH), and other sleep-wake disorders with normal orexin levels.

Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023

BOSTON and LONDON, March 28, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported recent business highlights and financial results for the fourth quarter and full-year ended December 31, 2023.

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023

See News Rankings